Eric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total value of $1,128,000.00. Following the sale, the chief operating officer now owns 732,294 shares in the company, valued at $8,260,276.32. This represents a 12.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Eric Venker also recently made the following trade(s):

• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The stock was sold at an average price of $11.54, for a total transaction of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The shares were sold at an average price of $11.82, for a total transaction of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.49, for a total transaction of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.32, for a total transaction of $1,132,000.00.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV traded down $0.11 during midday trading on Wednesday, hitting $11.16. The company’s stock had a trading volume of 3,451,499 shares, compared to its average volume of 4,690,415. Roivant Sciences Ltd. has a 1-year low of $9.69 and a 1-year high of $13.06. The firm’s fifty day moving average price is $11.75 and its 200-day moving average price is $11.60. The firm has a market cap of $8.12 billion, a P/E ratio of 1.98 and a beta of 1.27.

Hedge Funds Weigh In On Roivant Sciences

A number of large investors have recently bought and sold shares of ROIV. Gladius Capital Management LP bought a new position in shares of Roivant Sciences during the third quarter valued at approximately $35,000. Point72 Hong Kong Ltd acquired a new position in Roivant Sciences during the 2nd quarter valued at approximately $36,000. US Bancorp DE increased its position in Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after buying an additional 1,948 shares during the period. GAMMA Investing LLC grew its position in shares of Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after acquiring an additional 1,288 shares during the last quarter. Finally, Quarry LP bought a new position in Roivant Sciences in the 2nd quarter worth about $53,000. Institutional investors own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.93.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.